CR8426A - Anticuerpo del receptor anti-igf-i - Google Patents

Anticuerpo del receptor anti-igf-i

Info

Publication number
CR8426A
CR8426A CR8426A CR8426A CR8426A CR 8426 A CR8426 A CR 8426A CR 8426 A CR8426 A CR 8426A CR 8426 A CR8426 A CR 8426A CR 8426 A CR8426 A CR 8426A
Authority
CR
Costa Rica
Prior art keywords
antibodies
igf
cancer
receptor
elevated levels
Prior art date
Application number
CR8426A
Other languages
English (en)
Inventor
Singh Rajeeva
J Tavares Daniel
E Dagdigian Nancy
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/729,441 external-priority patent/US8034904B2/en
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of CR8426A publication Critical patent/CR8426A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

Los anticuerpos, anticuerpos humanizados, anticuerpos recubiertos, fragmentos de anticuerpo, anticuerpos derivatizados y conjugados de los mismos con agentes citotoxicos, que especificamente se enlazan a, e inhiben al receptor del factor I de crecimiento de tipo insulina, antagonizan los efectos de IGF-l, IGF-lI y suero en el crecimiento y supervivencia de celulas de tumor, y que substancialmente carecen de actividad agonista. Los anticuerpos y fragmentos de los mismos por consiguiente se pueden utilizar, opcionalmente en conjuncion con otros agente terapeuticos, en el tratamiento de tumores que expresan niveles elevados del receptor IGF-l, tales como cancer de pecho, cancer de colon, cancer de pulmon, sarcoma sinovial, cancer de prostata, y cancer pancreatico, y los anticuerpos derivatizados se pueden utilizar en el diagnostico y formacion de imagenes de tumores que expresan niveles elevados del IGF-I.
CR8426A 2003-12-08 2006-06-01 Anticuerpo del receptor anti-igf-i CR8426A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/729,441 US8034904B2 (en) 2002-06-14 2003-12-08 Anti-IGF-I receptor antibody

Publications (1)

Publication Number Publication Date
CR8426A true CR8426A (es) 2007-12-04

Family

ID=36616549

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8426A CR8426A (es) 2003-12-08 2006-06-01 Anticuerpo del receptor anti-igf-i

Country Status (13)

Country Link
EP (1) EP1692176A4 (es)
JP (1) JP2008502589A (es)
KR (1) KR20070001883A (es)
CN (1) CN1886424A (es)
AU (1) AU2004303792A1 (es)
BR (1) BRPI0417406A (es)
CA (1) CA2548065A1 (es)
CR (1) CR8426A (es)
EA (1) EA009807B1 (es)
EC (1) ECSP066595A (es)
IL (1) IL174770A0 (es)
MX (1) MXPA06005540A (es)
NO (1) NO20063155L (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG181834A1 (en) 2009-12-21 2012-07-30 Genentech Inc Antibody formulation
KR20130065665A (ko) * 2010-05-11 2013-06-19 아베오 파마슈티컬즈, 인크. 항-fgfr2 항체
EP2766478A4 (en) 2011-10-10 2015-06-17 Los Angeles Childrens Hospital NEW ASPARAGINASE AND METHOD FOR THE TREATMENT OF DISEASES RELATED TO ASPARAGINE DEPENDENCE
CN103509117B (zh) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 抗人her2和人igf-ir的双特异性抗体及其制备方法和用途
CN110691794B (zh) * 2017-05-30 2023-10-27 帝人制药株式会社 抗igf-i受体抗体
CN118615438A (zh) * 2023-03-07 2024-09-10 康方药业有限公司 包含抗ctla4-抗pd-1双特异性抗体的药物组合及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2351452A1 (en) * 1998-12-04 2000-06-15 Novartis Ag Methods and compositions useful for targeting activated vitronectin receptor .alpha.v.beta.3
EP2796468A2 (en) * 2001-01-05 2014-10-29 Pfizer Inc Antibodies to insulin-like growth factor I receptor
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
CA2514231A1 (en) * 2003-02-13 2004-08-26 Pfizer Products Inc. Uses of anti-insulin-like growth factor i receptor antibodies

Also Published As

Publication number Publication date
IL174770A0 (en) 2006-08-20
EP1692176A4 (en) 2008-11-12
EP1692176A1 (en) 2006-08-23
JP2008502589A (ja) 2008-01-31
CA2548065A1 (en) 2005-07-07
MXPA06005540A (es) 2006-08-17
EA200600931A1 (ru) 2006-10-27
AU2004303792A1 (en) 2005-07-07
EA009807B1 (ru) 2008-04-28
BRPI0417406A (pt) 2007-04-03
NO20063155L (no) 2006-08-11
KR20070001883A (ko) 2007-01-04
CN1886424A (zh) 2006-12-27
ECSP066595A (es) 2006-10-17

Similar Documents

Publication Publication Date Title
AR061911A1 (es) Anticuerpo antagonista para el tratamiento del cancer
ATE507244T1 (de) Anti-igf-i-rezeptor-antikörper
PE20080663A1 (es) Terapia tumoral con una combinacion de anticuerpos anti-her2
SG158119A1 (en) Anti-integrin immunoconjugates, methods and uses
AR070862A1 (es) Terapia de combinacion con antagonistas de c- met y her
CL2017001580A1 (es) Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped.
AR061245A1 (es) Composiciones y metodos para la modulacion del desarrollo vascular
PT2326665E (pt) Proteínas de fusão não citotóxicas compreendendo muteínas de egf
WO2006099141A3 (en) Anti-mesothelin antibodies
AR054175A1 (es) Nuevos anticuerpos anti-igf-ir y usos de los mismos
AR054254A1 (es) Terapia adyuvante con trastuzumab (herceptin registrado)
WO2006138729A3 (en) Receptor antagonists for treatment of metastatic bone cancer
DOP2013000045A (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
NZ599707A (en) Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
WO2007100640A3 (en) Growth hormone receptor antagonist cancer treatment
CR8426A (es) Anticuerpo del receptor anti-igf-i
WO2011137245A3 (en) Lytic-peptide-her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
CO6331345A2 (es) Composiciones y métodos que proporcionan una línea celular de hibridoma depositada como no. de acceso atcc pta-9387 y un anticuerpo producido por esta línea celular de hibridoma
EP1909783A4 (en) ILLUDIN ANALOGUE AS CANCER
Heller et al. Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer
EA200601405A1 (ru) Гуманизированное антитело
Shi et al. Antibody-drug conjugates in breast cancer: advances and prospects
JP2018516230A5 (es)
MD2849G2 (ro) Metodă de tratament al cancerului mamar la pacientele de vârstă înaintată
Abbasova et al. Neuroendocrine carcinoma of the prostate (review of the literature)

Legal Events

Date Code Title Description
FC Refusal